Amenorrhea as a rare drug-related adverse event associated with everolimus for pancreatic neuroendocrine tumors

被引:0
|
作者
Kawaguchi, Yoshiaki [1 ]
Maruno, Atsuko [1 ]
Kawashima, Yohei [1 ]
Ito, Hiroyuki [1 ]
Ogawa, Masami [1 ]
Mine, Tetsuya [1 ]
机构
[1] Tokai Univ, Dept Gastroenterol, Sch Med, Isehara, Kanagawa 2591193, Japan
关键词
Amenorrhea; Everolimus; Neuroendocrine tumor; Pancreas; Adverse event; TUBEROUS SCLEROSIS COMPLEX; CELL CARCINOMA; DOUBLE-BLIND; EFFICACY; TRIAL; MULTICENTER; OCTREOTIDE; RAPAMYCIN;
D O I
10.3748/wjg.v20.i42.15920
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The patient was an asymptomatic 43-year-old woman. Abdominal ultrasonography and enhanced computed tomography showed a tumor lesion accompanied by multiple cystic changes in the liver and the pancreatic tail. Endoscopic ultrasound-fine needle aspiration was performed on the pancreatic tumor lesion and revealed pancreatic neuroendocrine tumor (PNET). As it was unresectable due to multiple liver metastases, the decision was made to initiate treatment with everolimus and transcatheter arterial chemoembolization. The patient ceased menstruating after the start of everolimus administration. When the administration was discontinued due to interstitial lung disease, menstruation resumed, but then again stopped with everolimus resumption. An association between everolimus and amenorrhea was highly suspected. Amenorrhea occurred as a rare adverse event of everolimus. As the younger women might be included in PNETs patients, we should put this adverse event into consideration. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:15920 / 15924
页数:5
相关论文
共 50 条
  • [1] Amenorrhea as a rare drug-related adverse event associated with everolimus for pancreatic neuroendocrine tumors
    Yoshiaki Kawaguchi
    Atsuko Maruno
    Yohei Kawashima
    Hiroyuki Ito
    Masami Ogawa
    Tetsuya Mine
    World Journal of Gastroenterology, 2014, (42) : 15920 - 15924
  • [2] Sunitinib and everolimus in pancreatic neuroendocrine tumors
    Procopio, Giuseppe
    Pusceddu, Sara
    Buzzoni, Roberto
    TUMORI, 2012, 98 (03) : 394 - 394
  • [3] Role of everolimus in pancreatic neuroendocrine tumors
    Goldstein, Robert
    Meyer, Tim
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (11) : 1653 - 1665
  • [4] Everolimus for the treatment of pancreatic neuroendocrine tumors
    Feldmann, Georg
    Bisht, Savita
    Schuette, Ute
    Haarmann, Jens
    Brossart, Peter
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (14) : 2073 - 2084
  • [5] Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
    Yao, James C.
    Shah, Manisha H.
    Ito, Tetsuhide
    Bohas, Catherine Lombard
    Wolin, Edward M.
    Van Cutsem, Eric
    Hobday, Timothy J.
    Okusaka, Takuji
    Capdevila, Jaume
    de Vries, Elisabeth G. E.
    Tomassetti, Paola
    Pavel, Marianne E.
    Hoosen, Sakina
    Haas, Tomas
    Lincy, Jeremie
    Lebwohl, David
    Oberg, Kjell
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (06): : 514 - 523
  • [6] Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors
    Pavel, Marianne E.
    Chen, David
    He, Wei
    Cushman, Stephanie
    Voi, Maurizio
    de Vries, Elisabeth G. E.
    Baudin, Eric
    Yao, James C.
    PANCREAS, 2017, 46 (06) : 751 - 757
  • [7] Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience
    Yao, James C.
    Phan, Alexandria T.
    Jehl, Valentine
    Shah, Gaurav
    Meric-Bernstam, Funda
    CANCER RESEARCH, 2013, 73 (05) : 1449 - 1453
  • [8] Polypharmacy and adverse drug-related events
    Everett, WW
    ANNALS OF EMERGENCY MEDICINE, 2003, 41 (02) : 278 - 279
  • [9] Adverse clinical outcomes associated with drug-related hospitalizations in people with dementia
    Zaidi, Anum Saqib
    Peterson, Gregory M.
    Curtain, Colin M.
    Salahudeen, Mohammed S.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, 17 (01) : 73 - 78
  • [10] Inducing, Understanding and Overcoming Resistance to Everolimus in Pancreatic Neuroendocrine Tumors
    Vandamme, T.
    Op de Beeck, K.
    Beyens, M.
    Mortier, G.
    Pauwels, P.
    Van Camp, G.
    De Herder, W.
    Peeters, M.
    Holand, L. J.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 225 - 226